Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(0.25) per share. This is a 28.57 percent increase over losses of $(0.35) per share from the same period last year.
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc’s (NYSE:MRK) supplemental marketing…